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Background: Prostaglandins play an important role in ureteral obstruction, but the detailed expression profiles of
the prostaglandin receptors (PTGER1, PTGER2, PTGER3, PTGER4, PTGFR) remain unknown in the different parts of the
human ureter.
Methods: The expression pattern of PTGER1, PTGER2, PTGER3, PTGER4 and PTGFR was determined in human distal,
mid and proximal ureter and renal pelvis samples using immunohistochemistry (protein levels) and quantitative
real-time PCR (mRNA).
Results: PTGER1 was highly expressed in most samples irrespective of the ureteral localization; however, urothelial
cells had higher levels of PTGER1 than smooth muscle cells. PTGFR was also moderately to strongly expressed in
urothelial and smooth muscle cells. In comparison, PTGER2-4 expression was mostly unexpressed or weakly
expressed in urothelial and smooth cells in all regions.
Conclusions: Our data indicate high levels of PTGER1 in ureters.
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Inhibition of cyclooxygenase (COX) activity and the con-
current reduction of prostaglandin synthesis via non-
steroidal anti-inflammatory drugs (NSAIDs) are reported
to reduce pain, pressure and ureteral contractility in
patients experiencing ureteric colic or obstruction [1].
The synthesis of prostaglandins in patients with
obstructed ureters contributes to alterations in renal
hemodynamic function during ureteral obstruction, thus
recent studies indicate NSAIDs to be beneficial in these
patients. Especially COX2 mRNA has been shown to be
upregulated in obstructed ureters and represents a valu-
able pharmaceutical target in patients with urolithiasis
[2]. Potential toxic side effects of COX inhibitors include
a decrease in renal perfusion, inhibition of platelet ag-
gregation and gastric ulcerations. Beside COX-inhibitors,
prostanoids (PG) represent an estimable physiological* Correspondence: joerg.ellinger@ukb.uni-bonn.de
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reproduction in any medium, provided the ortarget in obstructed ureters: Granting that PGs consti-
tute an heterogeneous group, PGF2a (prostaglandin F2a)
and PGD2 (prostaglandin D2) cause ureteral contractil-
ity, PGE2 (prostaglandin E2) acts condition-dependent
via four receptor subtypes (PTGER1-4) while PTGER1
(prostaglandin E receptor 1; alias EP1) and PTGER3
(prostaglandin E receptor 3; EP3) induce smooth-muscle
contractility and PTGER2 (prostaglandin E receptor 2;
EP2) and PTGER4 (prostaglandin E receptor 4; EP4)
contribute to smooth muscle relaxation. PGE2-receptors
represent G-protein coupled receptors which act via dif-
ferent signal transduction pathways: cAMP stimulation
via Gq (PTGER2 and PTGER4), cAMP inhibition via Gi
(PTGER3) or activation via phosphatidylinositol hydroly-
sis (PTGER1) [3]. The existence of PGE2-receptor sub-
types has been verified in numerous animal models [1],
yet the distribution of PGE2 receptors in the human
urinary tract is not sufficiently examined. The impact of
PTGER2 and PTGER3 is subject to further present stud-
ies, investigating the suppression of cytokine production
[4] and the modulation of bone-related diseases [5]. Our
study investigates the expression profiles of PTGER1-4This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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lial and smooth muscle cells in the renal pelvis, prox-
imal, mid and distal human ureter. High expression
profiles of PTGER1 and PTGER3 in obstructed ureters
could contribute to new treatment approaches, comple-
menting the therapy of urolithiasis as an alternative
to the widespread use of COX inhibitors to provide
superior efficacy while minimizing potential side effects
of current therapy strategies.
Methods
Tissue samples
Tissue samples were obtained from 17 patients with ma-
lignant kidney tumors (renal cell carcinoma and urothe-
lial cell carcinoma of the renal pelvis) and 6 patients
with non-malignant disease undergoing nephroureter-
ectomy for hydronephrotic kidney (chronic pyeloneph-
ritis, n=1; vesicoureteral reflux, n=2; obstructive
megaureter, n=1; ureteropelvic junction obstruction,
n=1; unknown etiology, n=1). Separate samples from the
proximal ureter, mid ureter, distal ureter and renal pelvis
of the above mentioned patients were embedded in par-
affin after formalin-fixation (FFPE). Ureter samples from
3 patients were archived as fresh-frozen (FF) tissue and
stored at −80°C. All tissue samples were collected within
the framework of the Biobank at the Universitätsklini-
kum Bonn. All patients gave written informed consent
prior to the collection of tissues. This study has been
approved by the ethical committee of the University of
Bonn, Germany (approval number 036/08).
Immunohistochemistry
FFPE tissues were deparaffinized with xylol/ethanol
and rehydrated; FF sections were warmed up at room
temperature and rehydrated. The slides were then
placed in citrate buffer (pH 5.0-6.0) for optimal label-
ing and cooked in a microwave for 20 minutes at 600
W. After cooling for 30 minutes, the slides were
rehydrated, incubated in hydrogen peroxide for 10
minutes to block the peroxidase and washed with
Tris-buffered saline with Tween (0.01% Tween 20, pH
7.6). The antibodies (PTGER1: Cayman, #101740, di-
lution 1:100; PTGER2: Sigma-Aldrich, #P7747, 1:500;
PTGER3: Sigma-Aldrich, #HPA010689, 1:80; PTGER4:
Sigma-Aldrich, #HPA012756, 1:100; PTGFR: Sigma-
Aldrich, #NLS3890, 1:200; IgG: Dako, # P8622) were
solved in Antibody Diluent (Dako, # K6008) and incu-
bated overnight at 4°C. The slides were then washed with
Tris-buffered saline with Tween. Afterwards, the EnVision
Kit (Dako, #K4003) was used for visualization. Counter-
staining was performed with haematoxylin. Staining was
evaluated by a single investigator (M.O.). Human benign
uterus was used as negative and kidney as positive control.
In preliminary experiments, we have also investigated theexpression pattern of target proteins in bladder, renal,
ovary, colon and liver tissue (data not shown). The stain-
ing patterns were analogous to literature descriptions.
Quantitative Real-Time PCR
RNA was isolated from FFPE and FF tissue of the renal
pelvis, proximal ureter, mid ureter and distal ureter
using the RecoverAll Total Nucleic Acid Isolation Kit
for FFPE (Ambion, Foster City, CA, USA) according the
manufacturers recommendations. We did not perform
laser microdissection for separate analysis of urotheliale
and muscle cells because of the low amount of tissue.
Reverse transcription was performed using the SuperScript
III Reverse Transcriptase Kit (Invitrogen, Carlsbad, CA,
USA) and quantitative real-time PCR was performed using
the SYBR GreenER Kit (Invitrogen); primer sequences are
listed in Table 1. Each plate included a positive (kidney
tissue) and negative control (uterus) and a water blank.
PCR experiments were done with an ABI Prism 7900HT
(Applied Biosystems, Foster City, CA, USA).
Statistical analysis
All statistical tests were performed using IBM SPSS Sta-
tistics v20. The chi-square test was used to compare
protein expression levels in urothelial and smooth
muscle cells, and different parts of the human ureter re-
spectively. The Friedman-test for paired-samples was ap-
plied to compare protein expression levels in different
ureter samples. Statistical significance was concluded
at p < 0.05.
Results
Immunohistochemistry
Initially, we compared immunohistochemical staining of
FF and FFPE tissue. The evaluation of FF tissue staining
results was limited due to the fact that urothelial cells
detached from muscle tissue. Thus, we restricted the
analysis below to FFPE tissue. It should be noted that
staining results of muscle cells were similar in FF and
FFPE tissues.
We observed cytoplasmic expression of PTGER1-4
and PTGFR (see Figure 1). The target proteins were
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given sample, and therefore protein expression was
scored negative, low, moderate or high in a sample. We
did not notice expression differences in obstructed and
non-obstructed ureter tissues (p > 0.28, Mann–Whitney-
U-test). The expression of each target protein was mark-
edly different in the ureters (see Figure 2), and also the
expression level of the proteins was different in the vari-
ous parts of the ureter and renal pelvis (Friedman-
test: p < 0.001; see Additional file 1: Table S1 for expres-
sion profiles in the different samples):
- PTGER1 was expressed in most samples, but
expression was increased in urothelial compared to
smooth muscle cells. Most samples demonstrated high
PTGER1 expression levels in urothelial cells, whereas
muscle cells were expressing PTGER1 at moderate
levels. Further analysis of PTGER1 expression profiles
depicted comparable expression profiles in the renal
pelvis, as well as the lower, mid and proximal ureter.
- PTGER2 expression was less prevalent: Urothelial
cells demonstrated limited staining, irrespective of the
localization in the examined ureter. In comparison,Figure 1 Representative staining of PTGER1-4 and PTGFR in the humanPTGER2 expression profiles showed weak staining of
muscle cells in 15-20% of the ureter samples. PTGER2
expression was shown to be undetected in muscle cells
located in the renal pelvis.
- PTGER3 was rarely detected in urothelial cells (10%) of
the renal pelvis and the distal and proximal ureter. In
comparison, PTGER3 was more prevalent in the smooth
muscle cells, with different expression profiles, depending
on the ureter localization: Expression profiles were lower
in the upper parts of the examined ureters. In total, 62%
of the distal ureter, 80% of the mid ureter, 46% of the
proximal ureter and 23% of the renal pelvis samples
expressed PTGER3 at low or moderate levels.
- PTGER4 expression was low, and detected more
frequently in urothelial cells than in muscle cells. Only
13% of distal ureter muscle cells were expressing PTGER4
at low levels. PTGER4 expression was also low in
urothelial cells, but detected in the distal ureter (23%), mid
ureter (14%), proximal ureter (33%) and renal pelvis (31%).
- PTGFR expression was detected in most of the ureter
samples: Less than 15% of the samples had
undetectable PTGFR levels. The expression of PTGFR
was similar in urothelial and smooth muscle cells.ureter and renal pelvis.
Figure 2 Bar diagrams demonstrate expression levels of PTGER1-4 and PTGFR in urothelial and smooth muscle cells of the human
ureter.
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We next investigated the expression profiles of PTGER1-4
and PTGFR mRNA in ureter tissue. We first tried to exam-
ine mRNA in FFPE materials. Most probably due to the
low amount of available material and the consequences of
formalin-fixation, the amount and quality of RNA was not
sufficient for PCR experiments: We did neither detect any
target gene nor the reference genes ACTB and GAPDH inthe ureter tissue. We therefore used FF tissue for PCR.
Again, the low amount of each tissue impeded the mRNA
quantification: the expression levels of the target genes were
only marginal above the quantification limit (Cq values 30
to 32); the stability values for ACTB and GAPDH were
0,538 (as determined using the DataAssist software). All
three samples had detectable amounts of PTGER1-4 and
PTGFR mRNA. But, mRNA and protein levels (detected by
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related (all p > 0.3). Small amount of mRNA were even
detected in samples without traceable corresponding
protein. See Table 2.
Discussion
The analysis of prostaglandin receptor expression profiles
in obstructed human ureters plays an important role in the
attempt to implement new therapy strategies with better ef-
ficiency and reduced side effects in comparison to current
standards. Previous studies have already documented the
role and significance of prostaglandin receptors in animal
models [1], leaving the need to analyze distribution profiles
in the human urinary tract. By now, non-steroidal anti-in-
flammatory drugs (NSAIDs) are widespread used against
acute pain. Especially COX2 has been demonstrated to
show an increased expression in obstructed ureters and
represents a valuable target for selective COX2 inhibitors,
such as parecoxib [1]. Selective and non-selective COX-
inhibitors have many side effects such as gastrointestinal
side effects and a promotion of bleeding [6]. NSAIDs are
also under suspicion to cause renal dysfunction, such as salt
and fluid retention and hypertension [7]. Even acute renal
failure is a possible adverse reaction [8]. In the view of po-
tential side effects, recent studies have demonstrated the ef-
fect of PGE2 on obstructed ureters: Lowry et al. showed
that PGE2 increases contractility in obstructed ureters and
relaxes non-obstructed ureters [9]. The demonstrated
condition-dependence of PGE2 receptors might be
contributed to its various subtypes [10]: While Regan et al.
[11] report that PTGER2 and PTGER4 subtypes relax
smooth-muscle contractility, Neves et al. [12] showed aTable 2 Comparison of prostaglandin receptors’ mRNA and p
PTGER1 PTGER2
PCR IHC PCR IHC
A-distal 1.00 +++ 1.00 ++
A-middle 1.44 ++ 0.31 +
A-proximal 3.15 +++ 0.62 +
A-renal pelvis 2.73 ++ 0.55 -
B-distal 0.61 ++ 0.14 ++
B-middle 0.41 ++ 0.22 ++
B-proximal 0.21 ++ 0.20 +
B-renal pelvis 1.09 ++ 0.30 +
C-distal 1.28 +++ 0.46 ++
C-proximal 1.11 ++ 0.36 ++
C-renal pelvis 3.51 + 0.29 +
Note: Sample A: pyelonephritis, non-obstructed; Sample B: hydronephrotic kidney, n
Abbreviations: - = −; + = +; ++ = ++; +++ = +++; = tissue not available.contractile effect, mediated by PTGER1 and PTGER3. Our
study demonstrates high expression profiles of PTGER1 in
urothelial cells of the renal pelvis (100%) as well as the
proximal ureter (80%) decreasing rates to the distal part of
the ureter. Accordingly, smooth muscle cells showed mod-
erate to high expression profiles of PTGER1, especially in
the proximal part of ureters (85%). So far, PTGER1 expres-
sion profiles have sufficiently been examined for bladder
urothelial cells [13]. Ikeda et al. state that PTGER1 recep-
tors in the urothelium of the bladder may facilitate the
inflammation-induced micturition reflex via primary nerve
activity [13]. On the other hand Johansson et al. were re-
cently able to demonstrate the significant contribution of
PTGER1 receptors to inflammation induced pain [14].
Interestingly, PTGER1 receptors play an important role in
resolving inflammation through down-regulation of COX2
[15]. This aspect, along with strong expression profiles of
PTGER1 in our study, underlines the need to introduce a
selective PTGER1 antagonist complementary to the use of
COX2 inhibitors.
PTGER1 receptor antagonists have been shown to have
an excellent profile in inflammatory models [16]. So far, the
activation of PTGER1 has been shown to specifically acti-
vate the action of aldosterone on epithelial sodium channels
expression in the renal medulla [17]. Concurrently, Ankem
et al. [10] indicate that the PTGER3 subtype of the PGE2
receptor is involved in hypercontractility during ureteral
obstruction. However, the authors conclude that PTGER3
is not the sole factor contributing to the condition depend-
ency of prostaglandin receptors. Our study shows consist-
ent results with weak to moderate expression profiles of
PTGER3 in smooth muscle cells of the proximal, mid androtein levels in different ureteral locations
PTGER3 PTGER4 PTGFR
PCR IHC PCR IHC PCR IHC
1.00 - 1.00 + 1.00 +++
0.37 +++ 1.27 - 0.34 ++
0.42 - 1.09 + 0.64 ++
0.36 1.63 0.55
0.69 ++ 0.67 - 0.31 +
0.95 ++ 0.87 - 0.31 ++
1.04 ++ 0.83 - 0.30 +++
0.76 + 1.00 0.33
0.73 ++ 0.81 - 0.59 +++
1.23 ++ 0.84 - 0.64 ++
2.14 + 1.80 0.49
on-obstructed; Sample C: renal cella carcinoma, non-obstructed
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cells. PTGER3 receptors may function via cAMP response
elements (CRE) [18] and have been shown to be useful tar-
gets for anti-inflammatory therapy in cutaneous inflamma-
tion [19]. In contrast, PTGER2 and PTGER4 subtypes
showed negative to weak expression profiles in urothelial as
well as smooth muscle cells.
Some limitations of our study need to be discussed: upper
urinary tract tissue samples were obtained from patients
with different pathologies (cancer, chronic pyelonephritis,
vesicoureteral reflux, obstructive megaureter, ureteropelvic
junction obstruction) and obstructive and non-obstructive
ureters. Associated chronic inflammatory states - although
excessive infiltration of tissues with leukocytes was not
seen - altering prostaglandin receptor expression patterns
may influence the results. Furthermore, PCR experiments
were hindered by RNA degradation, and data interpret-
ation has to be done with caution. It has to be mentioned
that the collection of large numbers of urinary tract sam-
ples with an homogenous clinic is difficult; a larger cohort
might demonstrate differences of prostaglandin receptor
expression in obstructive and non-obstructive ureters.
Conclusions
High expression levels of PTGER1 in obstructed ureters
support rational drug development, as e.g. EPS antagonists,
to complement complement the treatment of patients with
urolithiasis as an alternative to the widespread and un-
selective use of COX2 inhibitors to provide superior effi-
ciency while minimizing potential side effects.
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